|
Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter …
DailyFinance We estimate that approximately $82 million of TECFIDERA revenues in the second quarter represent inventory in the channel while revenue generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from … Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking Alpha |
Gujarat FDCA & GSCBT ink pact to disseminate info on blood donation camps … – pharmabiz.com
Gujarat FDCA & GSCBT ink pact to disseminate info on blood donation camps …pharmabiz.comIn a move to check the authenticity of the blood donation camps routinely conducted in the state by different organisations, the Gujarat Food and Drug Control…
Patients With Donors Still Wait Months for Transplants as Kidney Disease Rises … – Big News Network.com
Patients With Donors Still Wait Months for Transplants as Kidney Disease Rises …Big News Network.comSRINAGAR, INDIAN-ADMINISTERED KASHMIR Sajad Ahmad, 15, is deep in thought as dialysis machines click and whir around him. The teenager is … New regu…
Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results – Earnings Call … – Seeking Alpha
Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results – Earnings Call …Seeking AlphaAnother presentation was on the combination use of idelalisib and rituximab in elderly treatment naive CLL SLL patients. In this study, the overall response rate…
Transplant May Boost Survival in Obese Kidney Failure Patients – Health.com
Transplant May Boost Survival in Obese Kidney Failure PatientsHealth.comThe researchers found that patients with a BMI of 30 to 39 gained a similar survival advantage from kidney transplantation as non-obese patients, which was a 66 percent lower risk …
READER SUBMITTED: Golf Tournament in Memory of Windsor Man to Fund … – Hartford Courant
READER SUBMITTED: Golf Tournament in Memory of Windsor Man to Fund …Hartford CourantProceeds from the tournament and banquet will go to the Connecticut Kidney Transplantation Research & Organ Donor Awareness Fund, Inc., which was founded by McDer…
Chabad rabbi shot, seriously wounded in Dagestan – Jerusalem Post
Chabad rabbi shot, seriously wounded in DagestanJerusalem PostIsakov, identified as chief rabbi of Derbent by Chabad sources, was wounded in the lung after being shot from behind by an unidentified assailant not far from his home. The attack took place…
Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter … – MarketWatch
|
Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter …
MarketWatch RITUXAN(R) (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012. “With a strong start for TECFIDERA in the U.S., as well as approvals in … Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking Alpha |
Celgene Corporation (CELG) CEO Discusses Q2 2013 Results – Earnings Call … – Seeking Alpha
Celgene Corporation (CELG) CEO Discusses Q2 2013 Results – Earnings Call …Seeking AlphaThe results for the CALGB 5803 Phase II study of REVLIMID plus rituximab in patients with previously untreated follicular lymphoma were presented during the Intern…
Gilead Sciences Announces Second Quarter 2013 Financial Results – DailyFinance
|
Gilead Sciences Announces Second Quarter 2013 Financial Results
DailyFinance Results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101) in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia. This regimen achieved a complete response rate of 19 percent and an … Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results – Earnings Call …Seeking Alpha |